Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089260 | 1.00 | REN (0.46) | RENCHRM1USP30PTPRBPTPN11 | |
| SCHEMBL4911019 | 0.91 | REN (0.49) | RENUSP30PTPRBPTPN11SLC2A1 | |
| SCHEMBL14089259 | 0.91 | REN (0.49) | RENUSP30PTPRBPTPN11SLC2A1 | |
| SCHEMBL4911727 | 0.88 | REN (0.49) | RENUSP30 | |
| SCHEMBL14089253 | 0.88 | REN (0.49) | RENUSP30 | |
| SCHEMBL4903326 | 0.84 | REN (0.51) | RENUSP30 | |
| SCHEMBL14089243 | 0.84 | REN (0.51) | RENUSP30 | |
| SCHEMBL14089232 | 0.82 | REN (0.51) | RENUSP30PTPRBPTPN11 | |
| SCHEMBL4910578 | 0.82 | REN (0.51) | RENUSP30PTPRBPTPN11 | |
| SCHEMBL4911786 | 0.82 | REN (0.48) | RENUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885CHRM1 2249/4885USP30 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.